Heartbeam, Inc.

Greetings and welcome to the HeartBeam fourth quarter and full year 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to hand the call over to Larry Holub, Director at MZ Group. Larry?

Good afternoon and welcome to HeartBeam's Financial Results Call. Today's conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wires this afternoon at 4.01 Eastern Time and is available in the Investor Relations section of our company's website, heartbeam.com. Your hosts today, Branislav Botic, Chief Executive Officer and Founder, John Hunt, Chief Business Officer, and Rick Bronstein, Chief Financial Officer, will present results of operations for the fourth quarter and full year ended December 31st, 2021. At this time, I would like to turn the call over to HeartBeam Chief Executive Officer, Branislav Vanec.

Thank you, Larry, and good afternoon, everyone. I'm pleased to welcome you to today's fourth quarter and full year 2021. financial result conference call. Our fourth quarter was highlighted by HeartBeam's most significant event to date, our successful IPO on NASDAQ Exchange that resulted in net proceeds of $14.9 million and set the company on course for several additional milestones during the fourth quarter and into the 2022. With the rapid pace of our product timeline, we have positioned the company for rollout success with a number of key hires to broaden our depth and reach. At the executive level, Alan Baumel was appointed as chief operating officer. His deep experience with cardiac devices and extensive industry knowledge will be instrumental in managing the preparations to accelerate and scale our commercialization path as well ready our products for the FDA submissions. We have also begun establishing our scientific advisory board with the appointment on world-renowned Harvard cardiologist Dr. Mike Gibson as chairman to drive our success and use of our technology. And we have further rounded out our capabilities with additional staff in sales, IT and cybersecurity, Q&A, documentation control, support, and electronics QMS, technical support, customer support, and accounting. We have also signed an agreement with Libmore Inc. and Triple Ring Technologies that will help bring our technologies to commercialization, and finally, we have partners with Phoebe Putney Health Systems for our first pilot study of our emergency department or ED heart attack or MI software detection technology. Our commercial team has identified key target accounts for both the HeartBeam ED and telehealth products and have engaged in a number of productive discussions on partnering with these key institutions. The target accounts include large academic institutions, regional healthcare systems in the Southeast and Mid-Atlantic, and regional community systems in the Western U.S. Some of these include Piedmont Health, WellSTAR, Emory, A&T Wake Forest, WellSpan Health, UCLA, Harborview, and Century. There has been a very positive response to our technology and several systems are willing to conduct pilot evaluations of our ED software solution as soon as we receive FDA clearance. The goal for the commercial team is indeed to transition the participating centers to a revenue account at the conclusion of these pilot studies. We look forward to ongoing conversations with these healthcare leaders moving forward. For those of you joining us for the first time or whom I have not had the opportunity to meet, I'd like to take a moment to introduce Heartbeam's products and our opportunity. Remote heart attack detection is a huge, well-known, and previously unsolved problem with a massive worldwide market. We have developed a system used by patients at home to help their physicians assess whether chest pain that they're experiencing is the result of a heart attack or MI. Our telemedicine solution can be used by patients at home to help their physician assess whether chest pain is the result of a heart attack. Based on very strong feedback actually received from the emergency department physicians, we developed a software tool for highly accurate detection of heart attacks in the ED emergency department setting. Our ED MI software product enables emergency departments to rapidly detect the heart attacks in patients. Both of these products share a common technology based on our 3D cardiac signal collection and processing. By developing our proprietary 3D vector signal-based technology, we have addressed a huge unmet need and enormous market opportunity. Most of you are familiar with the market for atrial fibrillation or AFib detection and key players. That market size is defined, actually, by the prevalence of AFib patients in the U.S., of which there are approximately 3 million. It is estimated to be a $2 billion market. The AFib detection space has many players, and some of them AliveCore and Apple Watch, to name just two of them. The market for heart attack detection outside of a medical facility is much larger. It is determined by about 18 million people in the United States that are at high risk for a heart attack. This is, in our estimate, a $10 billion opportunity in the U.S. alone. Of particular interest to us, and we believe the early adopters will be individuals that already survived a heart attack. There are about eight million people in the United States that fall into this category. They are at very high risk for another heart attack, and indeed, we believe that these individuals and their cardiologists will be leading the adoption of our telehealth technology. The telehealth is a very rapidly emerging solution that has dramatically increased with the onset of COVID-19 and is being driven by government policies to promote its use along with the rise of chronic conditions and an aging population in the United States. Indeed, we are seeing on many levels that patient care is moving to the patient and outside of the four walls of a medical institution. and we strongly believe that this trend will only accelerate. Again, bringing our telehealth product to cardiac patients and their physicians will present a major advancement for cardiac patients. Cardiovascular illness is the number one cause of death in the United States, and it presents a huge telehealth market opportunity. I would like now to turn the call over to John Hunt, our Chief Business Officer, to give you further details on product development and customer updates. John.